Rigel Tumbles on Phase III RA Failure; Lilly Drug Misses, Too

AstraZeneca plc's top-line results from a Phase IIb study of fostamatinib in rheumatoid arthritis showed that the drug was superior to placebo at six weeks, but it fell short of a secondary goal of noninferiority against Humira, sending shares of partner Rigel Pharmaceuticals Inc. plunging by almost 35 percent.